CA2654563A1 - Cytomegalovirus surface protein complex for use in vaccines and as a drug target - Google Patents

Cytomegalovirus surface protein complex for use in vaccines and as a drug target Download PDF

Info

Publication number
CA2654563A1
CA2654563A1 CA002654563A CA2654563A CA2654563A1 CA 2654563 A1 CA2654563 A1 CA 2654563A1 CA 002654563 A CA002654563 A CA 002654563A CA 2654563 A CA2654563 A CA 2654563A CA 2654563 A1 CA2654563 A1 CA 2654563A1
Authority
CA
Canada
Prior art keywords
cmv
pul128
pul130
antibodies
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002654563A
Other languages
English (en)
French (fr)
Inventor
Thomas Shenk
Dai Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2654563(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2654563A1 publication Critical patent/CA2654563A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002654563A 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target Abandoned CA2654563A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81168906P 2006-06-07 2006-06-07
US60/811,689 2006-06-07
US90254407P 2007-02-20 2007-02-20
US60/902,544 2007-02-20
PCT/US2007/013365 WO2007146024A2 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target

Publications (1)

Publication Number Publication Date
CA2654563A1 true CA2654563A1 (en) 2007-12-21

Family

ID=38832360

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002654563A Abandoned CA2654563A1 (en) 2006-06-07 2007-06-06 Cytomegalovirus surface protein complex for use in vaccines and as a drug target

Country Status (5)

Country Link
US (5) US7704510B2 (https=)
EP (2) EP3031469B1 (https=)
JP (3) JP5822433B2 (https=)
CA (1) CA2654563A1 (https=)
WO (1) WO2007146024A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
EP2144627A1 (en) * 2007-05-11 2010-01-20 Vakzine Projekt Management GmbH Composition containing hcmv particles
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
AU2009223688B2 (en) * 2008-03-10 2014-12-11 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
AU2013202400B2 (en) * 2008-07-16 2014-10-09 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
AU2012203417B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
AU2008359583B2 (en) * 2008-07-16 2012-04-05 Institute For Research In Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
DK2352759T3 (en) 2008-07-16 2017-12-18 Inst Res Biomedicine ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUS AND USE THEREOF
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
WO2011057124A1 (en) 2009-11-06 2011-05-12 Transtarget, Inc. Polyclonal bispecific antibody compositions and method of use
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
EP2614072A4 (en) * 2010-09-09 2014-03-19 Univ Virginia Commonwealth VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
WO2012047732A2 (en) * 2010-09-29 2012-04-12 Genentech, Inc. Antibody compositions and methods of use
WO2012051211A2 (en) * 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
EP2667874A4 (en) * 2011-01-27 2014-07-30 Univ Princeton MTOR KINASE HEMMER AS ANTIVIRUS AGENT
EP2729165B1 (en) * 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
US20140348863A1 (en) * 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
BR112014024023A2 (pt) * 2012-03-28 2017-07-18 Genentech Inc anticorpos idiotípicos anti-hcmv e usos dos mesmos
CA2878344A1 (en) * 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
CN110241137A (zh) * 2012-07-27 2019-09-17 希望之城 一种递送ul128复合体和预防cmv感染的mva疫苗
CN109045294A (zh) * 2013-01-10 2018-12-21 思齐乐 流感病毒免疫原性组合物及其应用
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016014660A (es) * 2014-05-08 2017-02-28 Pfizer Medios y metodos para el tratamiento de cmv.
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
US11572389B2 (en) * 2017-01-27 2023-02-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
CA3060019A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
US11524069B2 (en) * 2017-09-13 2022-12-13 Sanofi Pasteur Human cytomegalovirus immunogenic composition
CN112512569A (zh) * 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
CN113271968B (zh) 2018-10-17 2024-06-14 葛兰素史密丝克莱恩生物有限公司 经修饰的巨细胞病毒蛋白和稳定化的复合物
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2020208082A1 (en) * 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
CN115698298A (zh) * 2020-06-09 2023-02-03 Km生物医薬股份公司 巨细胞病毒的gB与五聚体的融合蛋白和包含该融合蛋白的疫苗
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
EP4192494A4 (en) * 2020-08-06 2024-11-13 La Jolla Institute for Immunology Methods for treating and preventing cytomegalovirus infection
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
TWI843471B (zh) * 2022-03-11 2024-05-21 財團法人國家衛生研究院 含抗原和dna之組成物及其用途
WO2025231404A1 (en) * 2024-05-03 2025-11-06 The Trustees Of Princeton University Telomerase inhibition for treating or inhibiting herpesvirus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
US20040087001A1 (en) * 2001-02-21 2004-05-06 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
DE10232322A1 (de) 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
EP3031469B1 (en) * 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof

Also Published As

Publication number Publication date
EP3031469B1 (en) 2023-08-23
JP2009539845A (ja) 2009-11-19
US20110200633A1 (en) 2011-08-18
US11129891B2 (en) 2021-09-28
US8173362B2 (en) 2012-05-08
US20140370026A1 (en) 2014-12-18
EP2037959A2 (en) 2009-03-25
WO2007146024A2 (en) 2007-12-21
US20080187545A1 (en) 2008-08-07
WO2007146024A3 (en) 2008-03-20
EP3031469A1 (en) 2016-06-15
JP2013241442A (ja) 2013-12-05
US20120226023A1 (en) 2012-09-06
JP6274770B2 (ja) 2018-02-07
JP5822433B2 (ja) 2015-11-24
US20190358317A1 (en) 2019-11-28
JP2016128418A (ja) 2016-07-14
US7704510B2 (en) 2010-04-27
US8828399B2 (en) 2014-09-09
EP2037959B1 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
US11129891B2 (en) Cytomegalovirus surface protein complex for use in vaccines and as a drug target
JP6345753B2 (ja) ヒトサイトメガロウイルス中和抗体およびその使用
Kropff et al. Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies
CN102812043A (zh) 用于制备t细胞受体样单克隆抗体的方法及其用途
KR20140041951A (ko) 인간 사이토메갈바이러스 중화 항체 및 이의 용도
Giugni et al. Neutralization of human cytomegalovirus by human CD13-specific antibodies
JPH02500951A (ja) ヒトサイトメガロウイルスの免疫原性糖ペプチド
Trudel et al. Comparison of caprine, human and bovine strains of respiratory syncytial virus
US20200255499A1 (en) Antibody to Epstein Barr Virus and Uses Thereof
Gonczol et al. Progress in vaccine development for prevention of human cytomegalovirus infection
US20200171135A1 (en) CMV Vaccine and Method of Making and Using the Same
CN116162154A (zh) 抗人巨细胞病毒抗体及其用途
Morenkov et al. Immunological characterisation of glycoprotein E of Aujeszky's disease virus
WO1991002004A1 (en) IMMUNOGENIC GLYCOPROTEINS OF HUMAN CYTOMEGALOVIRUS gCII
Persson Berg Viral proteins as serological antigens-Development and clinical applications
Padilla et al. Varicella-zoster virus with a lost gE epitope: evidence for immunological pressure by the human antibody response
Kropff et al. Glycoprotein N of Human Cytomegalovirus Protects the Virus from Neutralizing
Pötzsch et al. B Cell Repertoire Analysis Identifies New Antigenic Domains on Glycoprotein B of
Wiegers Neutralizing Antibodies to Antigenic Domain 5 of Glycoprotein B of Human Cytomegalovirus
Herrman Neutralizing Antibodies to Epstein Barr Virus in the Rhesus Macaque Animal Model and in Humans
Padilla et al. Departments of Microbiology & Pediatrics, University of Iowa, Iowa City, Iowa, USA

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20211214